Abbott Announces Commercial Availability Of Oncodetect Molecular Residual Disease Test

Benzinga · 3d ago

Abbott (NYSE: ABT) today announced the commercial availability of its next-generation Oncodetect® MRD test, a personalized, tumor-informed, whole-genome sequencing test designed to provide molecular insights during and after cancer treatment.